IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Disease conditions associated with pulmonary fibrosis are progressive and have a poor long-term prognosis with irreversible changes in airway architecture leading to marked morbidity and mortalities. Using murine models we demonstrate a role for interleukin (IL)-25 in the generation of pulmonary fibrosis. Mechanistically, we identify IL-13 release from type 2 innate lymphoid cells (ILC2) as sufficient to drive collagen deposition in the lungs of challenged mice and suggest this as a potential mechanism through which IL-25 is acting. Additionally, we demonstrate that in human idiopathic pulmonary fibrosis there is increased pulmonary expression of IL-25 and also observe a population ILC2 in the lungs of idiopathic pulmonary fibrosis patients. Collectively, we present an innate mechanism for the generation of pulmonary fibrosis, via IL-25 and ILC2, that occurs independently of T-cell-mediated antigen-specific immune responses. These results suggest the potential of therapeutically targeting IL-25 and ILC2 for the treatment of human fibrotic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“confirming a critical role for type 2 cytokine signaling in the progression of fibrosis”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [139]
In the citing paper
“IL-13, IL-4R, and IL-13Rβ1-deficient mice as well as animals treated with neutralizing antibodies to IL-13 or IL-4R display reduced fibrosis following many different types of tissue injury136–140”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [139]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells
Moro, K., Yamada, T., Tanabe, M., Takeuchi, T., Ikawa, T., Kawamoto, H., Furusawa, J.-I., Ohtani, M., Fujii, H., & Koyasu, S. (2010) · Nature · doi:10.1038/nature08636 · Cited by 1,992
Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity
Neill, D. R., Wong, S. H., Bellosi, A., Flynn, R. J., Daly, M., Langford, T. K. A., Bucks, C., Kane, C. M., Fallon, P. G., Pannell, R., et al. (2010) · Nature · doi:10.1038/nature08900 · Cited by 1,938 · cited 4×
“IL-25– (10), IL-17BR– (11), T1/ST2- (37), TSLPR- (38), IL-13– (39), and A”
BackgroundSelf-citationSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus
Monticelli, L. A., Sonnenberg, G. F., Abt, M. C., Alenghat, T., Ziegler, C. G. K., Doering, T. A., Angelosanto, J. M., Laidlaw, B. J., Yang, C. Y., Sathaliyawala, T., et al. (2011) · Nature Immunology · doi:10.1038/ni.2131 · Cited by 1,321 · cited 2×
“The ILC2 population in IPF patients is similar to those previously seen in human lung tissue and BAL (16, 27), but this is an observation of these cells in association with pulmonary fibrosis.”
BackgroundResultA Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308 · cited 2×
“J Allergy Clin Immunol 128(1):116–124.”
BackgroundInnate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus
Monticelli (2011) · PubMed · doi:10.1031/ni.2131 · Cited by 1,286
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274 · cited 2×
“However, to develop more effective therapeutics for fibrotic lung diseases a greater understanding of the pathogenesis and the underlying mechanisms that lead to pulmonary fibrosis is needed (3, 4).”
BackgroundIL-25 Induces IL-4, IL-5, and IL-13 and Th2-Associated Pathologies In Vivo
Fort, M. M., Cheung, J., Yen, D., Li, J., Zurawski, S. M., Lo, S., Menon, S., Clifford, T., Hunte, B., Lesley, R., et al. (2001) · Immunity · doi:10.1016/s1074-7613(01)00243-6 · Cited by 1,203 · cited 1×
“In murine studies intranasal administration of IL-25 results in evidence of pulmonary tissue remodeling including development of perivascular fibrosis, and intratracheal administration results in increased pulmonary Th2 cytokines and airways hyper-reactivity (AHR) (17, 18), whereas blocking IL-25 reduces AHR severity…”
BackgroundMjösberg, J. M., Trifari, S., Crellin, N. K., Peters, C. P., van Drunen, C. M., Piet, B., Fokkens, W. J., Cupedo, T., & Spits, H. (2011) · Nature Immunology · doi:10.1038/ni.2104 · Cited by 1,166 · cited 3×
“ILC2 have previously been identified both in healthy lung tissue and tissue from asthma, rhinosinitis, and influenza patients (16), implying a role for these cells in pulmonary inflammation.”
BackgroundResultSystemically dispersed innate IL-13–expressing cells in type 2 immunity
Price, A. E., Liang, H.-E., Sullivan, B. M., Reinhardt, R. L., Eisley, C. J., Erle, D. J., & Locksley, R. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003988107 · Cited by 1,131
Wynn, T. A. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141142 · Cited by 958 · cited 1×
“IL-13 is now widely linked to a range of fibrotic conditions (7) including asthma, where IL-13 is being targeted as a therapy (8).”
BackgroundFallon, P. G., Ballantyne, S. J., Mangan, N. E., Barlow, J. L., Dasvarma, A., Hewett, D. R., McIlgorm, A., Jolin, H. E., & McKenzie, A. N. J. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051615 · Cited by 738 · cited 2×
“IL-25– (10), IL-17BR– (11), T1/ST2- (37), TSLPR- (38), IL-13– (39), and A”
BackgroundSelf-citationInnate Lymphoid Cells Promote Anatomical Containment of Lymphoid-Resident Commensal Bacteria
Sonnenberg, G. F., Monticelli, L. A., Alenghat, T., Fung, T. C., Hutnick, N. A., Kunisawa, J., Shibata, N., Grunberg, S., Sinha, R., Zahm, A. M., et al. (2012) · Science · doi:10.1126/science.1222551 · Cited by 737 · cited 1×
“Murine data have already provided evidence on both the role of type 2 cytokines and innate lymphoid cells on the progression of inflammation and fibrosis at several mucosal sites (11, 12, 27, 28).”
BackgroundBleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092121 · Cited by 730
Pulmonary fibrosis: patterns and perpetrators
Noble, P. W., Barkauskas, C. E., & Jiang, D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60323 · Cited by 595 · cited 2×
“However, to develop more effective therapeutics for fibrotic lung diseases a greater understanding of the pathogenesis and the underlying mechanisms that lead to pulmonary fibrosis is needed (3, 4).”
BackgroundTranscription factor RORα is critical for nuocyte development
Wong, S. H., Walker, J. A., Jolin, H. E., Drynan, L. F., Hams, E., Camelo, A., Barlow, J. L., Neill, D. R., Panova, V., Koch, U., et al. (2012) · Nature Immunology · doi:10.1038/ni.2208 · Cited by 576 · cited 1×
“To address the role of ILC2 in pulmonary fibrosis, ILC2-deficient staggerer (Rora) mice, which have RORα deficiency, were used (26).”
MethodSelf-citationCD4+ Lymphoid Tissue-Inducer Cells Promote Innate Immunity in the Gut
Sonnenberg, G. F., Monticelli, L. A., Elloso, M. M., Fouser, L. A., & Artis, D. (2011) · Immunity · doi:10.1016/j.immuni.2010.12.009 · Cited by 572 · cited 1×
“CD90 disparate chimeras were generated using methods previously described (29).”
MethodIL25 elicits a multipotent progenitor cell population that promotes TH2 cytokine responses
Saenz, S. A., Siracusa, M. C., Perrigoue, J. G., Spencer, S. P., Urban Jr, J. F., Tocker, J. E., Budelsky, A. L., Kleinschek, M. A., Kastelein, R. A., Kambayashi, T., et al. (2010) · Nature · doi:10.1038/nature08901 · Cited by 555
Interleukin 25 promotes the initiation of proallergic type 2 responses
Angkasekwinai, P., Park, H., Wang, Y.-H., Wang, Y.-H., Chang, S. H., Corry, D. B., Liu, Y.-J., Zhu, Z., & Dong, C. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061675 · Cited by 554 · cited 1×
“In murine studies intranasal administration of IL-25 results in evidence of pulmonary tissue remodeling including development of perivascular fibrosis, and intratracheal administration results in increased pulmonary Th2 cytokines and airways hyper-reactivity (AHR) (17, 18), whereas blocking IL-25 reduces AHR severity…”
BackgroundTownsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E., & McKenzie, A. N. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.1069 · Cited by 482
Self-citationBasophils Produce IL-4 and Accumulate in Tissues after Infection with a Th2-inducing Parasite
Min, B., Prout, M., Hu-Li, J., Zhu, J., Jankovic, D., Morgan, E. S., Urban, J. F., Dvorak, A. M., Finkelman, F. D., LeGros, G., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040590 · Cited by 443 · cited 1×
“In addition to CD4 T cells, basophils are an early source of IL-4 and IL-13 in innate type 2 responses (21, 22).”
BackgroundFallon, P. G., Richardson, E. J., McKenzie, G. J., & McKenzie, A. N. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2585 · Cited by 403
Self-citationBarlow, J. L., Peel, S., Fox, J., Panova, V., Hardman, C. S., Camelo, A., Bucks, C., Wu, X., Kane, C. M., Neill, D. R., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.012 · Cited by 383 · cited 2×
“Proc Natl Acad Sci USA 107(25):11489–11494.”
BackgroundSelf-citationImpaired Development of Th2 Cells in IL-13-Deficient Mice
McKenzie, G. J., Emson, C. L., Bell, S. E., Anderson, S., Fallon, P., Zurawski, G., Murray, R., Grencis, R., & McKenzie, A. N. J. (1998) · Immunity · doi:10.1016/s1074-7613(00)80625-1 · Cited by 381 · cited 1×
“IL-25– (10), IL-17BR– (11), T1/ST2- (37), TSLPR- (38), IL-13– (39), and A”
Self-citationIL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β Independent
Kaviratne, M., Hesse, M., Leusink, M., Cheever, A. W., Davies, S. J., McKerrow, J. H., Wakefield, L. M., Letterio, J. J., & Wynn, T. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4020 · Cited by 370
Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma
Ballantyne, S. J., Barlow, J. L., Jolin, H. E., Nath, P., Williams, A. S., Chung, K. F., Sturton, G., Wong, S. H., & McKenzie, A. N. J. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.07.051 · Cited by 368 · cited 1×
“In murine studies intranasal administration of IL-25 results in evidence of pulmonary tissue remodeling including development of perivascular fibrosis, and intratracheal administration results in increased pulmonary Th2 cytokines and airways hyper-reactivity (AHR) (17, 18), whereas blocking IL-25 reduces AHR severity…”
BackgroundSelf-citationAmu, S., Saunders, S. P., Kronenberg, M., Mangan, N. E., Atzberger, A., & Fallon, P. G. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.01.018 · Cited by 368 · cited 1×
“Lung collagen was analyzed using the Sircol collagen assay (Biocolor Life Science Assays) as described (43).”
MethodSelf-citationIL-4 Induces Characteristic Th2 Responses Even in the Combined Absence of IL-5, IL-9, and IL-13
Fallon, P. G., Jolin, H. E., Smith, P., Emson, C. L., Townsend, M. J., Fallon, R., Smith, P., & McKenzie, A. N. J. (2002) · Immunity · doi:10.1016/s1074-7613(02)00332-1 · Cited by 354
Self-citationBasophils Orchestrate Chronic Allergic Dermatitis and Protective Immunity against Helminths
Ohnmacht, C., Schwartz, C., Panzer, M., Schiedewitz, I., Naumann, R., & Voehringer, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.011 · Cited by 343 · cited 2×
“Mcpt8Cre mice (23) experiments were performed in the Department of Infection Biology, Universitätsklinikum Erlangen, Germany.”
BackgroundMethodSelf-citationBarron, L., & Wynn, T. A. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00414.2010 · Cited by 304 · cited 1×
“In the context of the cellular source of IL-13 in the generation of fibrosis, CD4 T helper (h) 2 cells are implicated (9).”
BackgroundPeriostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis
Naik, P. K., Bozyk, P. D., Bentley, J. K., Popova, A. P., Birch, C. M., Wilke, C. A., Fry, C. D., White, E. S., Sisson, T. H., Tayob, N., et al. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00139.2012 · Cited by 260 · cited 2×
“3748) with periostin levels, an extracellular matrix protein associated with IPF and lung remodeling (32), in BAL from IPF patients (Fig.”
BackgroundA Role for Thymic Stromal Lymphopoietin in CD4+ T Cell Development
Al-Shami, A., Spolski, R., Kelly, J., Fry, T., Schwartzberg, P. L., Pandey, A., Mackall, C. L., & Leonard, W. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031975 · Cited by 240
Chiaramonte, M. G., Schopf, L. R., Neben, T. Y., Cheever, A. W., Donaldson, D. D., & Wynn, T. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.2.920 · Cited by 214 · cited 3×
“The cytokine IL-13 was first implicated in fibrosis using profibrotic eggs from the type 2 cytokine-inducing pathogen Schistosoma mansoni, in the presence of a soluble IL-13Rα2-Fc fusion protein (5) and in Il13 mice (6).”
BackgroundInfluentialCorrigan, C. J., Wang, W., Meng, Q., Fang, C., Eid, G., Caballero, M. R., Lv, Z., An, Y., Wang, Y.-H., Liu, Y.-J., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.03.043 · Cited by 189 · cited 1×
“Recent studies have implicated IL-25 and ILC2 in the pathogenesis of pulmonary conditions in both murine models and human conditions such as allergic asthma (12, 13, 15, 16).”
BackgroundTGF-β, Smad3 and the process of progressive fibrosis
Gauldie, J., Bonniaud, P., Sime, P., Ask, K., & Kolb, M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350661 · Cited by 183
Selman, M., King, T. E., & Pardo, A. (2001) · Cited by 144
IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts
Letuve, S., Lajoie-Kadoch, S., Audusseau, S., Rothenberg, M. E., Fiset, P., Ludwig, M. S., & Hamid, Q. A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.025 · Cited by 117 · cited 1×
“Studies on human fibroblasts, known as a prominent source of TGFβ in wound healing and fibrosis (35), have shown that fibroblasts respond to IL-25, they express IL-17BR, and produce TGFβ (36).”
BackgroundSchistosoma mansoni in IL-4-deficient mice
Pearce, E. J., Cheever, A. W., Leonard, S., Covalesky, M., Fernandez-Botrán, R., Köhler, G., & Köpf, M. (1996) · International Immunology · doi:10.1093/intimm/8.4.435 · Cited by 117 · cited 1×
“Regarding the reduction in IL-4 expression, a cytokine shown to be important in the generation of egg-associated granuloma formation (20), in”
BackgroundIL-13 Overexpression Predisposes to Anaphylaxis Following Antigen Sensitization
Fallon, P. G., Emson, C. L., Smith, P., & McKenzie, A. N. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2712 · Cited by 84
Self-citationT1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation
Mangan, N. E., Dasvarma, A., McKenzie, A. N. J., & Fallon, P. G. (2007) · European Journal of Immunology · doi:10.1002/eji.200636520 · Cited by 68 · cited 2×
“Tissue was homogenized and prepared as previously described (42).”
MethodSelf-citationInnate type 2 cells and asthma
Hams, E., & Fallon, P. G. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.001 · Cited by 57 · cited 4×
“IL-25– (10), IL-17BR– (11), T1/ST2- (37), TSLPR- (38), IL-13– (39), and 370 | www.pnas.org/cgi/doi/10.1073/pnas.1315854111 Hams et al. staggerer-Rorasg/sg–deficient mice (Jackson Laboratories) were bred in-house on a BALB/c background.”
BackgroundSelf-citationBasophils are recruited to inflamed lungs and exacerbate memory T h2 responses in mice and humans
Wakahara, K., Van, V. Q., Baba, N., Bégin, P., Rubio, M., Delespesse, G., & Sarfati, M. (2012) · Allergy · doi:10.1111/all.12072 · Cited by 55 · cited 1×
“In addition to CD4 T cells, basophils are an early source of IL-4 and IL-13 in innate type 2 responses (21, 22).”
BackgroundAsthma Phenotypes and Interleukin-13 — Moving Closer to Personalized Medicine
Kraft, M. (2011) · New England Journal of Medicine · doi:10.1056/nejme1108666 · Cited by 50 · cited 1×
“IL-13 is now widely linked to a range of fibrotic conditions (7) including asthma, where IL-13 is being targeted as a therapy (8).”
BackgroundCopy Number Variation of FCGR3B Is Associated with Susceptibility to Idiopathic Pulmonary Fibrosis
Bournazos, S., Bournazou, I., Murchison, J. T., Wallace, W. A., McFarlane, P., Hirani, N., Simpson, A. J., Dransfield, I., & Hart, S. P. (2010) · Respiration · doi:10.1159/000321997 · Cited by 26 · cited 1×
“Surgical lung biopsy and/or BAL was performed as described previously (41).”
Self-citation
Cited by
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
The IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
“This feedforward cellular response between tuft cells and ILC2 greatly enhances mucus production for worm expulsion and type 2 immunity against the parasitic infection.”
BackgroundInfluentialLiver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Inflammation and metabolism in tissue repair and regeneration
Eming, S. A., Wynn, T. A., & Martin, P. (2017) · Science · doi:10.1126/science.aam7928 · Cited by 1,369
Liver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310
Metadata
- Authors
- Hams, E., Armstrong, M. E., Barlow, J. L., Saunders, S. P., Schwartz, C., Cooke, G., Fahy, R. J., Crotty, T. B., Hirani, N., Flynn, R. J., Voehringer, D., McKenzie, A. N. J., Donnelly, S. C., & Fallon, P. G.
- Affiliations
- Trinity College Dublin (IE)
- MRC Laboratory of Molecular Biology (GB)
- Universitätsklinikum Erlangen (DE)
- University College Dublin (IE)
- St. James's Hospital (IE)
- St. Vincent's University Hospital (IE)
- Medical Research Council Centre for Inflammation Research, University of Edinburgh, Edinburgh EH16 4SB, United Kingdom;
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-12-16
- Volume
- 111
- Issue
- 1
- Pages
- 367-372
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3890791
- OpenAlex
- W2042237784
- Cited by
- 376
- References
- 45
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 21 · 2023: 25 · 2022: 26 · 2021: 41 · 2020: 34 · 2019: 40 · 2018: 30 · 2017: 39 · 2016: 25 · 2015: 38 · 2014: 19
- FWCI
- 22.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arrow@dit (Dublin Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- IL-25, ILC2, pulmonary fibrosis, idiopathic pulmonary fibrosis, IL-13, collagen deposition, innate immunity, airway remodeling, therapeutic targeting
- MeSH terms
- Aged, Animals, Collagen, Female, Gene Expression Regulation, Humans, Immunity, Innate, Inflammation, Interleukins, Liver, Lung, Lymphocytes, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Middle Aged, Pulmonary Fibrosis, Schistosoma mansoni, Cell Adhesion Molecules, Interleukin-13, Interleukin-17, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.